InvestSMART

InhaleRx Limited (ASX:IRX)

ALERT: Price-sensitive ASX Announcement for IRX
Current share price for IRX : $0.028 -0.008 (-22.22%)+
Announcement
Release
26 Nov 2025 10:41AM
Price at Release
$0.036
Full Release
download
Summary
InhaleRx Limited, based in Melbourne, Australia, announced plans to expand its drug development pipeline with the inclusion of SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression (TRD). The company completed a share placement to raise $750,000 and will conduct a rights issue to raise an additional $250,000. SRX-25 aims to improve patient accessibility and adherence over existing treatments with its oral formulation and will proceed via the 505(b)(2) regulatory pathway to expedite development. Funding support is secured from the Linlithgow Family Office, totaling $52.3 million. Additionally, InhaleRx plans to rebrand as Nexalis Therapeutics Limited, marking a strategic shift from inhaled therapies to broader drug development initiatives.
Key Points
  • InhaleRx announced plans to add SRX-25, a new oral fixed-dose combination therapy for Treatment-Resistant Depression, to their clinical development pipeline.
  • The company completed a placement of shares at 2.5 cents to raise approximately $750,000 and will undertake a Non-Renounceable Rights Issue Offer to raise an additional $250,000.
  • SRX-25 is designed to improve accessibility and adherence compared to the current intranasal esketamine formulations by Johnson & Johnson.
  • InhaleRx will pursue the development of SRX-25 through the US FDA’s 505(b)(2) regulatory pathway, leveraging existing safety data.
  • The development plan includes a Phase 1 pharmacokinetic study followed by a Phase 2 proof-of-concept trial.
  • Additional funding for SRX-25 development will be provided by the Linlithgow Family Office, bringing the total funding commitment to approximately $52.3 million.
  • Subject to shareholder approval, the company plans to rebrand as Nexalis Therapeutics Limited and focus on drug development beyond inhalation therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.